Welcome to our dedicated page for Novo Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo Nordisk A/S stock.
Novo Nordisk A/S develops, manufactures and markets medicines for serious chronic diseases, with a core franchise in diabetes care and obesity treatment. News for NVO commonly centers on GLP-1 products such as Wegovy, including FDA approvals for new formulations and indications, U.S. launch and access initiatives, and clinical data tied to weight management, cardiovascular risk factors and metabolic liver disease.
Company updates also cover investigational programs such as CagriSema, pipeline results in related therapeutic areas, patient-safety actions involving compounded semaglutide, collaborations with pharmacy or telehealth channels, and capital-allocation matters such as share repurchase activity.
Novo Nordisk has extended its COVID-19 Patient Assistance Program until June 30, 2021 to help individuals losing health insurance due to job changes from the pandemic. The program offers free insulin for 90 days to eligible patients. Additionally, those enrolled in the My$99Insulin program need to re-register for 2021 eligibility. Novo Nordisk also promotes various affordability initiatives, including the long-standing Patient Assistance Program and Copay Savings Cards. For details on eligibility and options, visit NovoCare.com.
Novo Nordisk has received FDA approval for an updated label for Saxenda® (liraglutide) 3 mg, allowing its use in adolescents (ages 12-17) with obesity. Saxenda, initially approved in 2014 for adults, now addresses a significant and growing need for effective treatments in youth, where obesity rates have doubled. The approval is supported by a phase 3a clinical trial showing significant reductions in BMI and weight compared to placebo. Common side effects include gastrointestinal issues. This move highlights the company's commitment to addressing adolescent obesity.